BioXcel Therapeutics Inc. (NASDAQ: BTAI)
$1.22
+0.0050 ( +0.41% ) 390.1K
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Market Data
Open
$1.22
Previous close
$1.21
Volume
390.1K
Market cap
$45.79M
Day range
$1.19 - $1.28
52 week range
$1.04 - $12.21
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jul 16, 2024 |
8-k | 8K-related | 13 | Jun 25, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4/a | Other | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
8-k | 8K-related | 14 | Jun 12, 2024 |